Dr. Refaeli is an expert in the genetic manipulation of cells, regulation of gene expression and transformation in hematopoetic lineages. His research interests focus on three broad area: 1) the contribution of antigen receptor signaling to lymphoid neoplasica; 2) the role of role of proto-oncogenes in the regulation of lymphoid tolerance and disease; and 3) the role of MYC in the regulation of stem cell proliferation, survival, self-renewal and differentiation. Dr. Refaeli is Associate Professor, Charles C. Gates Program in Regenerative Medicine and Stem Cell Biology, Department of Dermatology, University of Colorado Denver School of Medicine. He received his Ph.D. from Harvard University and his A.B. degree from the University of Pennsylvania.
Dr. Turner has extensive experience in the areas of molecular biology and genetics, biochemistry and the genetic manipulation of viruses and various hematopoietic cell types, including stem cells, mature lymphoid and myeloid cells. In addition to his role at Taiga, Dr. Turner is Research Instructor, Charles C. Gates Program in Regenerative Medicine and Stem Cell Biology, Department of Dermatology, University of Colorado Denver School of Medicine. He received his Ph.D. from the University of Colorado Health Sciences Center, holds a Masters in Public Health from the Johns Hopkins School of Public Health and received his A.B. degree from Cornell University.
Dr. Bird is coordinating the basic science and genetic engineering of the blood stem cells used to generate human antibodies. Prior to joining Taiga Biotechnologies, Dr. Bird spent eight years as a scientist at biotechnology companies Cytokine Sciences and Sangamo BioSciences. He received his Ph.D. from the University of Colorado Health Sciences Center and his B.A. from the University of Colorado, Boulder.
Dr. Posada is currently CEO and Co-founder of Resolve Therapeutics, LLC, a Seattle-based private biotechnology company developing a novel biologic compound for the treatment of lupus. Dr. Posada is also the
owner of Posada & Associates, Inc. a consulting practice focused on assisting biotechnology clients with business strategy and partnering. Dr. Posada’s previous industry experience includes Chief Business
Officer at GlycoFi, Senior Director of Business Development at PDL BioPharma, and Manager of Biotechnology R&D at Eli Lilly and Company. He received his Ph.D. from the University of Vermont College of
Medicine, holds a Masters in Business Administration from the University of Vermont and received his B.S. from Eastern Connecticut State University.
